Pharmacokinetics of non-steroidal anti-inflammatory drugs

Bailliere's Clinical Rheumatology

Volumn 2, Issue 2, 1988, Pages 363-393

  Day, R O ^a   Graham, G G ^a   Williams, K M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT;

AGE; DRUG BLOOD LEVEL; DRUG EXCRETION; HUMAN; KIDNEY FUNCTION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; RHEUMATIC DISEASE; SEX DIFFERENCE; SHORT SURVEY; SYNOVIAL FLUID;

ABSORPTION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; HALF-LIFE; HUMAN; INTESTINAL ABSORPTION; METABOLIC CLEARANCE RATE; SYNOVIAL FLUID; TISSUE DISTRIBUTION;

EID: 0024224535     PISSN: 09503579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0950-3579(88)80019-0     Document Type: Article

References (103)

1. Anti-inflammatory (ibuprofen) drug therapy in rheumatoid arthritis-rate of response and lack of time-dependency of plasma pharmacokinetics
2. Non-steroidal anti-inflammatory drugs, plasma half-lives, and adverse reactions
3. Pharmacokinetics of ketoprofen in the elderly
4. The interaction between indomethacin and probenecid. A clinical and pharmacokinetic study
5. Indomethacin in rheumatoid arthritis: clinical effects, pharmacokinetics, and platelet studies in responders and non-responders
6. Thermography in the assessment of inflammatory arthritis
7. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knees
8. Salicyl phenolic glucuronide pharmacokinetics in patients with rheumatoid arthritis
9. Pharmacokinetics, efficacy and safety of diclofenac: elderly vs non-elderly arthritic patients
10. Pharmacokinetics of indomethacin in the neonate
11. Disposition of azapropazone in chronic renal failure and hepatic failure
12. Comparison of two dosing schedules of flurbiprofen for patients with rheumatoid arthritis. Twice-daily versus four-times-a-day schedules
13. Ibuprofen: a double-blind comparison of twice a day therapy with four times a day therapy
14. Non-steroid anti-inflammatory drugs: influence of extra-cellular pH on biodistribution and pharmacological effects
15. Anti-inflammatory analgesic responders and non-responders: a clinico-pharmacological study of flurbiprofen
16. Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprofen in patients with rheumatoid arthritis
17. Comparison of naproxen and piroxicam in the treatment of rheumatoid arthritis: a double-blind crossover study
18. Acute and chronic pharmacokinetic studies of slow release ketoprofen (Oruvail) in rheumatoid arthritis
19. Renal syndromes associated with non-steroidal anti-inflammatory drugs
20. A prospective endoscopic study of the effect of Orudis and Oruvail on the upper gastrointestinal tract, in patients with osteoarthritis
21. Relationships of serum naproxen concentration to efficacy in rheumatoid arthritis
22. Induction of salicyluric acid formation in rheumatoid arthritis patients treated with salicylates
23. Anti-rheumatic drug interactions
24. Effect of food and various antacids on the absorption of tenoxicam
25. Clinical pharmacology of non-steroidal anti-inflammatory drugs
26. Synovial fluid concentrations of the enantiomers of ibuprofen
27. Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers.
28. Tolmetin kinetics and synovial fluid prostaglandin E levels in rheumatoid arthritis
29. Enterohepatic circulation of sulindac and metabolites
30. Quantitation of dose and concentration-response relationship for fenclofenac in rheumatoid arthritis
31. Naproxen dose and concentration-response relationship in rheumatoid arthritis
32. Comparative trial of standard and sustained release formulations of ibuprofen in patients with osteoarthritis
33. Central and peripheral antialgesic action of aspirin-like drugs
34. Salicylate clearance, the resultant of protein binding and metabolism
35. Cognitive dysfunction associates with naproxen and ibuprofen in the elderly
36. Kinetics of non-steroidal anti-inflammatory drugs in synovial fluid
37. Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis
38. Aspects of the clinical pharmacology of anti-inflammatory drugs
39. Absorption and disposition of ibuprofen in the elderly
40. Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin
41. The pharmacokinetics of benzoxaprofen in elderly subjects
42. A pharmacokinetic interaction between phenobarbitone and fenoprofen, a new anti-inflammatory agent
43. The effects of age and sex on the disposition of acetylsalicylic acid and its metabolites
44. Piroxicam pharmacokinetics: recent clinical results relating kinetics and plasma levels to age, sex and adverse effects
45. Treatment of rheumatoid arthritis with fenoprofen: comparison with aspirin
46. Ibuprofen and sulindac kinetics in alcoholic liver disease
47. Pharmacokinetics and tolerance of slow-release indomethacin tablets in rheumatoid arthritis
48. Circadian variations in the signs and symptoms of rheumatoid arthritis and in the therapeutic effectiveness of flurbiprofen at different times of day
49. Stereoselective disposition of ibuprofen enantiomers in man
50. Timing optimizes sustained-release indomethacin treatment of osteoarthritis
51. Clinical pharmacokinetics of salicylates: a re-assessment.
52. Urine pH and salicylate therapy
53. Limited capacity for salicylphenolic glucuronide formation and its effect on the kinetics of salicylate elimination in man
54. A pharmacokinetic study of phenylbutazone-associated hypoplastic anaemia
55. The effect of organic acids on renal clearance of methotrexate in man
56. Effect of anti-inflammatory drugs on sulphated glycosaminoglycan synthesis in aged human articular cartilage
57. Pharmacokinetics of naproxen in elderly patients
58. The effect of renal dysfunction on the disposition of non-steroidal anti-inflammatory drugs forming acyl-glucuronides
59. Diflunisal disposition and hypouricaemic response in osteoarthritis
60. Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle
61. Enantioselective disposition of 2-arylpropionic acid nonsteroidal anti-inflammatory drugs. I. 2-Phenylpropionic acid disposition
62. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid
63. Salicylate metabolism: effects of age and sex in adults
64. Decreased steady-state salicylic acid plasma levels associated with chronic aspirin ingestion
65. Salicylate ototoxicity: a clinical study
66. Clinical pharmacology of the salicylates
67. Treatment of acute migraine attack: naproxen and placebo compared
68. Salicylate kinetics in old age
69. Rare adverse reactions to non-steroid anti-inflammatory drugs
70. Marked suppression by salicylate of the augmented proteoglycan synthesis in osteoarthritic cartilage
71. Effects of aspirin on salivary and serum phenytoin kinetics in healthy subjects
72. Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet aggregation in man
73. Effects of diclofenac on lithium kinetics
74. Pharmacokinetics of azapropazone in the elderly
75. Pharmacokinetics of aspirin and salicylate in elderly subjects and in patients with alcoholic liver disease
76. Aspirin pharmacokinetics in migraine. The effect of metoclopramide
77. Absorption kinetics of aspirin in man following oral administration of an aqueous solution
78. Stereoselective inversion of R-fenoprofen to S-fenoprofen in humans
79. Effects of sulindac and indomethacin on renal prostaglandin synthesis
80. Naprosyn metabolism in man
81. Plasma protein displacement interactions are rarely of clinical significance
82. Clinical pharmacokinetics of methotrexate
83. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy
84. Sulindac metabolism: the importance of the intact colon
85. Multicentre trial of naproxen and phenylbutazone in acute gout
86. Toxic interaction between acetazolamine and salicylate: case reports and a pharmacokinetic explanation
87. Effect of antacids on the bioavailability of diflunisal in the fasting and postprandial states
88. Relation of naproxen kinetics to effect on platelet prostaglandin release in men and dysmenorrheic women
89. Naproxen pharmacokinetics in the elderly
90. Naproxen pharmacokinetics in patients with rheumatoid arthritis during active polyarticular inflammation
91. Naproxen kinetics and disease activity in rheumatoid arthritis: a within-patient study
92. Diflunisal
93. Biotransformation of diflunisal and renal excretion of its glucuronides in renal insufficiency
94. Effect of aluminium hydroxide on diflunisal absorption
95. Comparative multiple dose kinetics of two formulations of indomethacin
96. The effect of salicylate on anatomically intact articular cartilage is influenced by sulphate and serum in the culture medium
97. Nonsteroidal antiinflammatory agents in rheumatoid arthritis and ankylosing spondylitis
98. Importance of drug enantiomers in clinical pharmacology
99. The stereoselective uptake of ibuprofen enantiomers into adipose tissue
100. Pharmacokinetic studies on diclofenac sodium in young and old volunteers
101. The pharmacokinetics of diclofenac sodium following intravenous and oral administration
102. The influence of food on the absorption of diclofenac as determined by the urinary excretion of the unchanged drug and its major metabolites during chronic administration
103. Rheuma-therapie bei Leberkranken